Edition:
India

AbbVie Inc (ABBV.N)

ABBV.N on New York Stock Exchange

97.45USD
15 Dec 2017
Change (% chg)

$1.15 (+1.19%)
Prev Close
$96.30
Open
$96.86
Day's High
$97.86
Day's Low
$96.64
Volume
6,724,398
Avg. Vol
1,652,667
52-wk High
$98.87
52-wk Low
$59.27

Chart for

About

AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology,... (more)

Overall

Beta: 1.53
Market Cap(Mil.): $144,249.59
Shares Outstanding(Mil.): 1,594.09
Dividend: 0.64
Yield (%): 2.83

Financials

  Industry Sector
P/E (TTM): -- 31.14 16.44
EPS (TTM): -- -- --
ROI: -- 14.86 10.62
ROE: -- 16.28 14.20

BRIEF-Imbruvica Plus Rituximab Phase 3 Innovate Trial In Rare Waldenström's Macroglobulinemia Met Primary Endpoint

* IMBRUVICA® (IBRUTINIB) PLUS RITUXIMAB PHASE 3 INNOVATE TRIAL IN RARE WALDENSTRÖM'S MACROGLOBULINEMIA MET PRIMARY ENDPOINT

05 Dec 2017

BRIEF-Enanta Pharma Says Abbvie’s Maviret ‍is Now Commercially Available In Japan​

* ENANTA PHARMACEUTICALS - ABBVIE'S MAVIRET HAS BEEN APPROVED FOR REIMBURSEMENT BY MINISTRY OF HEALTH, LABOUR AND WELFARE

30 Nov 2017

Roche, AbbVie leukemia drug superior to older medicine in study

Patients with a type of leukemia that had relapsed who received the new drug Venclexta in combination with Rituxan went significantly longer without the disease worsening than those treated with Rituxan and Treanda, according to interim results from a pivotal late stage study released on Tuesday.

21 Nov 2017

Roche, AbbVie leukemia drug superior to older medicine in study

Nov 21 Patients with a type of leukemia that had relapsed who received the new drug Venclexta in combination with Rituxan went significantly longer without the disease worsening than those treated with Rituxan and Treanda, according to interim results from a pivotal late stage study released on Tuesday.

21 Nov 2017

UPDATE 1-Novartis pitches new Cosentyx data as immunology crowd grows

* Cosentyx is now Novartis's No. 3 drug (Adds details about Cosentyx competition, comment from Novartis)

06 Nov 2017

BRIEF-AbbVie, on conf call, says we need to see HCV market sort itself out

* AbbVie CEO, on conf call, says we need to see HCV market sort itself out

27 Oct 2017

AbbVie says Humira sales will balloon to $21 billion in 2020, shares rise

AbbVie Inc forecast its flagship drug Humira to bring $21 billion in sales by 2020, about $3 billion higher than its expectation two years ago, driving the U.S. drugmaker's shares up 4 percent on Friday.

27 Oct 2017

UPDATE 2-AbbVie says Humira sales will balloon to $21 bln in 2020, shares rise

* Shares up 4 percent (Adds analyst comment, updates share price)

27 Oct 2017

BRIEF-Abbvie increases quarterly dividend by 11 percent

* Sets quarterly cash dividend of $0.71 per share Source text for Eikon: Further company coverage:

27 Oct 2017

AbbVie says Humira sales will balloon to $21 bln in 2020

Oct 27 AbbVie Inc on Friday forecast its flagship drug Humira to bring $21 billion in sales by 2020, about $3 billion higher than its expectation two years ago.

27 Oct 2017

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $142.46 +0.81
Pfizer Inc. (PFE.N) $37.20 +0.74
Novartis AG (NOVN.S) CHF83.80 -0.05
Merck & Co., Inc. (MRK.N) $56.24 +0.23
Roche Holding Ltd. (ROG.S) CHF244.10 +2.40
Roche Holding Ltd. (RO.S) CHF243.40 +0.90
Abbott Laboratories (ABT.N) $55.50 +0.77
Eli Lilly and Co (LLY.N) $86.54 +0.04
Sanofi SA (SASY.PA) €73.55 -0.22

Earnings vs. Estimates